Apricus Biosciences to Present at the 25th Annual ROTH Conference

Apricus Biosciences to Present at the 25th Annual ROTH Conference

SAN DIEGO, March 13, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that Steve Martin, Interim Chief Executive Officer and Chief Financial
Officer, will present at the 25th Annual ROTH Conference, being held at The
Ritz Carlton in Dana Point, CA. Mr. Martin's presentation will take place on
Monday, March 18, 2013 at 4:00 p.m. Pacific Time.

The presentation will be webcast and accessible to the public online at
http://wsw.com/webcast/roth27/apri/ or via the Company's website at
http://www.apricusbio.com. A replay will be available for 90 days after the
presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health. The Company has one approved product, Vitaros®, for the treatment of
erectile dysfunction, which will be marketed in Canada by Abbott Laboratories
and Femprox®, a product candidate, for the treatment of female sexual arousal
disorder, which successfully completed one 400-patient Phase III study in
China.

For further information on Apricus Bio, visit http://www.apricusbio.com. You
can also receive information at http://twitter.com/apricusbio.

CONTACT: Apricus Bio Investor Relations:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Apricus logo